Peptide Encyclopedia / Methylene Blue
EncyclopediaMethylene blue is a synthetic phenothiazine redox dye that converts methemoglobin back to functional hemoglobin. The FDA approved the ProvayBlue injection in 2016 for methemoglobinemia, while cognitive and longevity uses stay off-label and investigational. Educational only, not medical advice.
| Category | Cognitive |
| Regulatory status | FDA-approved as an injection (ProvayBlue, methylene blue injection USP; initial US approval 2016) for pediatric and adult acquired methemoglobinemia. |
A synthetic phenothiazine redox dye that, at low doses, reduces oxidized hemoglobin (Fe3+ methemoglobin) back to functional Fe2+ hemoglobin via NADPH-dependent reduction; it also has reported mitochondrial electron-cycling and monoamine oxidase-inhibitory properties relevant to investigational neuro/metabolic uses.
Approximately 5-6.5 hours (terminal half-life) reported for the injectable product.
FDA-approved as an injection (ProvayBlue, methylene blue injection USP; initial US approval 2016) for pediatric and adult acquired methemoglobinemia. Cognitive, antimicrobial, and longevity uses are not FDA-approved and are off-label/investigational; non-pharmaceutical 'lab grade' products are not for human use.
Can cause serotonin syndrome when combined with serotonergic drugs (it is an MAO inhibitor) and is contraindicated in G6PD deficiency (hemolysis risk) and pregnancy; may cause blue/green urine and skin discoloration, nausea, and dizziness. High doses can paradoxically cause methemoglobinemia.
Approved drug with established evidence for methemoglobinemia; cognitive/longevity applications are early/investigational with limited human data.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Methylene Blue may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
